BDSX
- Biodesix, Inc.
()
Overview
Company Summary
Biodesix, Inc. (BDSX) is a biotechnology company that specializes in the development and commercialization of blood-based diagnostic tests for the early detection and personalized treatment of various diseases, particularly cancer. The company utilizes advanced molecular profiling techniques to analyze genetic and proteomic information extracted from a patient's blood sample.
Biodesix focuses on creating tests that provide actionable information to physicians, helping them make informed decisions about patient diagnosis, prognosis, and treatment selection. The company's primary product, the VeriStrat� test, is designed to aid in the treatment decisions for patients with non-small cell lung cancer (NSCLC). VeriStrat provides information on the likelihood of a patient's response to different treatment options and helps physicians tailor therapies accordingly.
In addition to VeriStrat, Biodesix has developed additional diagnostic tests, such as GeneStrat� and Blood-Based Proteomic Correlates of Drug Safety (PRO-DOS�), to assist in the identification of the most appropriate treatment options for patients with lung cancer and other diseases.
Through its innovative approach to utilizing blood-based biomarkers, Biodesix aims to improve patient outcomes by enabling personalized medicine, reducing unnecessary treatments, minimizing the risk of adverse reactions to medications, and ultimately assisting healthcare providers in delivering precise and effective care.